Displaying 261 - 280 of 2013
Statement of Chair Lina M. Khan Regarding the Policy Statement Concerning Reliance on Prior PBM-Related Advocacy Statements and Reports
FTC Votes to Issue Statement Withdrawing Prior Pharmacy Benefit Manager Advocacy
Statement of Chair Lina M. Khan Joined by Commissioner Rebecca Kelly Slaughter and Commissioner Alvaro M. Bedoya Regarding FTC-DOJ Proposed Merger Guidelines
FTC and DOJ Seek Comment on Draft Merger Guidelines
FTC Sues to Block IQVIA’s Acquisition of Propel Media to Prevent Increased Concentration in Health Care Programmatic Advertising
Federal Trade Commission Withdraws Health Care Enforcement Policy Statements
FTC Announces Tentative Agenda for July 20 Open Commission Meeting
FTC Provides Testimony Before the House Judiciary Committee at Oversight Hearing
Commission Order Vacates ALJ Initial Decision and Dismisses Complaint in Case Against Altria and Juul
FTC Files Amicus Brief to Clarify Antitrust Standards Involving Exclusive-Dealing and Bundling Arrangements
Altria Group/JUUL Labs, In the Matter of
The Federal Trade Commission filed an administrative complaint alleging that Altria Group, Inc. and JUUL Labs, Inc. entered a series of agreements, including Altria’s acquisition of a 35% stake in JUUL, that eliminated competition in violation of federal antitrust laws. According to the complaint, this series of agreements involved Altria ceasing to compete in the U.S. market for closed-system electronic cigarettes in return for a substantial ownership interest in JUUL, by far the dominant player in that market. In an initial decision announced on Feb. 24, 2022, Chief Administrative Law Judge D. Michael Chappell dismissed the antitrust charges in the complaint.
FTC and DOJ Propose Changes to HSR Form for More Effective, Efficient Merger Review
Statement of Chair Lina M. Khan Joined by Commissioners Slaughter and Bedoya Regarding Proposed Amendments to the Premerger Notification Form and the Hart-Scott-Rodino Rules
FTC Files Amicus Brief in Bystolic Antitrust Litigation Supporting Competition in the Hypertension Drug Market
FTC Policy Director Issues Statement Commending Maine’s Repeal of Certificate of Public Advantage Law
Displaying 261 - 280 of 2013